Legal Representation
Attorney
Kevin M. Bovard
USPTO Deadlines
Next Deadline
57 days remaining
NOA E-Mailed - SOU Required
Due Date
February 25, 2026
Extension Available
Until August 25, 2026
Application History
16 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 12, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 11, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Aug 11, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 11, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 25, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 31, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 31, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 25, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 6, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 6, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 6, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 6, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 6, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Nov 15, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 27, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 1, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceuticals for the treatment of rare genetic diseases; pharmaceuticals for the treatment of musculo-skeletal disorders; pharmaceuticals for the treatment of skeletal dysplasia; pharmaceuticals for the treatment of cancer; pharmaceuticals for the treatment of cells that are resistant to drugs; pharmaceuticals for the treatment and prevention of drug resistance; anti-cancer pharmaceuticals
Class 042
Research and development of drugs in the fields of oncology, rare diseases, musculo-skeletal disorders, and skeletal dysplasia; scientific research for medical purposes in the fields of oncology, rare diseases, musculo-skeletal disorders, and skeletal dysplasia; clinical research in the fields of oncology, rare diseases, musculo-skeletal disorders, and skeletal dysplasia; scientific research and development of pharmaceuticals for the treatment of cancer, rare diseases, musculo-skeletal disorders, and skeletal dysplasia.
Class 044
providing medical information; providing medical information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; Providing a web site featuring medical information; Providing a website featuring information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; providing information in the field of pharmaceuticals; providing medical information in the field of oncology; providing a website featuring information in the field of the diagnosis and treatment of cancer.
Additional Information
Pseudo Mark
TYRA BIO SCIENCES
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOSCIENCES"